TSLP Proteins & ELISA Kits

Sign InRegister

English

TSLP Overview

Molecule Name

Thymic stromal lymphopoietin

Synonyms

TSLP

Drug Development Progress

Drugs in Clinical Trials28

Approved Drugs1

Highest Development StageApproved

Target Synonym

Thymic stromal lymphopoietin，TSLP

Background

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.

TSLP Product List

Molecule	Cat. No.	Product Name	Species	Host	Purity	Activity	Size&Price
TSLP	HOT TSP-H5243	Human TSLP Protein (R127A, R130A), His Tag, low endotoxin (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISABLIFlow	$380.00 100ug
TSLP	HOT TSP-H52Hb	Human TSLP Protein, His Tag, premium grade	Human	HEK293	MSMALSSDS-PAGE	ELISASPRBLIFlowCELL BASE	$415.00 100ug
TSLP	HOTAvitag TSP-H82Eb	Biotinylated Human TSLP Protein, His,Avitag™ (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISABLIFlow	$415.00 25ug
TSLP	HOT TSP-M52H8	Mouse TSLP Protein, His Tag (MALS verified)	Mouse	HEK293	MALSSDS-PAGE	ELISA	$380.00 100ug
TSLP	HOT TSP-C52H4	Cynomolgus TSLP (R127A, R130S) Protein, His Tag, low endotoxin (HPLC verified)	Cynomolgus	HEK293	HPLCSDS-PAGE	ELISA	$430.00 100ug
TSLP	HOT TSP-C52H8	Cynomolgus TSLP Protein, His Tag (MALS verified)	Cynomolgus	HEK293	MALSSDS-PAGE	ELISA	$395.00 100ug
TSLP	Avitag TSP-C82E3	Biotinylated Cynomolgus TSLP Protein, His,Avitag™ (MALS verified)	Cynomolgus	HEK293	MALSSDS-PAGE	ELISA	$360.00 25ug
TSLP	TSP-H5253	Human TSLP Protein, Fc Tag, low endotoxin (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISASPR	$385.00 100ug
TSLP	TSP-H5254	Human TSLP (R127A, R130A) Protein, Fc Tag, low endotoxin (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISASPR	$385.00 100ug
TSLP	TSP-H5255	Human TSLP (R127A, R130A) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)	Human	HEK293	MALSSDS-PAGE	ELISAFlow	$380.00 100ug

TSLP >

Hot

Human TSLP Protein (R127A, R130A), His Tag, low endotoxin (MALS verified)

Cat. No. TSP-H5243

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISABLIFlow

$380.00

TSLP >

Hot

Human TSLP Protein, His Tag, premium grade

Cat. No. TSP-H52Hb

Species

Human

Host

HEK293

Purity

MSMALSSDS-PAGE

Activity

ELISASPRBLIFlowCELL BASE

$415.00

TSLP >

HotAvitag

Biotinylated Human TSLP Protein, His,Avitag™ (MALS verified)

Cat. No. TSP-H82Eb

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISABLIFlow

$415.00

TSLP >

Hot

Mouse TSLP Protein, His Tag (MALS verified)

Cat. No. TSP-M52H8

Species

Mouse

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$380.00

TSLP >

Hot

Cynomolgus TSLP (R127A, R130S) Protein, His Tag, low endotoxin (HPLC verified)

Cat. No. TSP-C52H4

Species

Cynomolgus

Host

HEK293

Purity

HPLCSDS-PAGE

Activity

ELISA

$430.00

TSLP >

Hot

Cynomolgus TSLP Protein, His Tag (MALS verified)

Cat. No. TSP-C52H8

Species

Cynomolgus

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$395.00

TSLP >

Avitag

Biotinylated Cynomolgus TSLP Protein, His,Avitag™ (MALS verified)

Cat. No. TSP-C82E3

Species

Cynomolgus

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISA

$360.00

TSLP >

Human TSLP Protein, Fc Tag, low endotoxin (MALS verified)

Cat. No. TSP-H5253

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISASPR

$385.00

TSLP >

Human TSLP (R127A, R130A) Protein, Fc Tag, low endotoxin (MALS verified)

Cat. No. TSP-H5254

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISASPR

$385.00

TSLP >

Human TSLP (R127A, R130A) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)

Cat. No. TSP-H5255

Species

Human

Host

HEK293

Purity

MALSSDS-PAGE

Activity

ELISAFlow

$380.00

You Have Viewed 1-10 Of 17 Results

No Data

FAQ

When should fluorescent DLL3 proteins or DLL3-coupled beads be used instead of unconjugated protein?

Fluorescent DLL3 supports direct flow-cytometric detection of DLL3-binding antibodies or engineered cells. DLL3-coupled beads are useful for binder capture, enrichment, or multivalent antigen presentation, while unconjugated protein remains preferable for quantitative kinetics.

How can soluble DLL3 protein and a DLL3 stable cell line be combined to reduce false-positive binders?

Use recombinant DLL3 for controlled affinity and epitope screening, then confirm hits on a DLL3 stable cell line. This filters candidates that recognize an isolated or tag-dependent epitope but poorly bind cell-surface DLL3.

How should I choose among full extracellular DLL3 and shorter DLL3 fragments for antibody discovery?

A broad extracellular construct is suitable for immunization and primary screening. Overlapping DLL3 fragments, such as residues 27–215, 176–492, and 353–492, can help localize epitopes before confirming binding to full-length cell-surface DLL3.

How should cross-species TL1A binding be assessed before selecting an in vivo model?

Screen candidates against human TL1A first, then compare cynomolgus or rhesus, mouse, and rat homologs under matched assay conditions. This distinguishes true species differences from changes caused by format or immobilization.

Which TL1A format is best for controlled immobilization in binding assays?

His-tagged TL1A supports standard capture formats, while Avitag™-biotinylated TL1A enables site-specific immobilization on streptavidin surfaces. The latter is useful when orientation and surface consistency are important for SPR, BLI, or ELISA.

Asset Licensing Opportunity

Resources

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
QL-2302	QL2302; QL-2302	Phase 3 Clinical	Qilu Pharmaceutical Co Ltd	Asthma	Details
GB-0895	GB-0895	Phase 3 Clinical	Generate Biomedicines Inc	Asthma; Immune System Diseases; Pulmonary Disease, Chronic Obstructive	Details
Tilrekimig	PF-07275315	Phase 3 Clinical	Pfizer Inc	Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive	Details
Lunsekimig	SAR-443765	Phase 3 Clinical	Sanofi	Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive	Details
Bosakitug	TQC-2731; BSI-045B; TQC2731; ATI-045	Phase 3 Clinical	Biosion Inc	Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis	Details
SHR-1905	SHR-1905; AIO-001; GSK-5784283	Phase 3 Clinical	Jiangsu Hengrui Medicine Co Ltd	Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis	Details
CM-326	CM-326	Phase 3 Clinical	Keymed Biosciences Co Ltd	Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis	Details
QX-008N	QX-008N; QX008N; JKN-2401; JKN2401; SNCA008; SNCA-008	Phase 3 Clinical	Qyuns Therapeutics Co Ltd	Asthma; Pulmonary Disease, Chronic Obstructive	Details
Solrikitug	NSI-8226; MK-8226	Phase 2 Clinical	Merck & Co Inc	Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Hypertension; Pulmonary Disease, Chronic Obstructive	Details
Ecleralimab	CSJ-117; NOV-14	Phase 2 Clinical	Novartis Pharma Ag	Asthma; Pulmonary Disease, Chronic Obstructive	Details
HBM-9378	HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378	Phase 2 Clinical	Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Asthma; Pulmonary Disease, Chronic Obstructive	Details
CM-512	CM512; CM-512	Phase 2 Clinical	Keymed Biosciences Co Ltd	Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis	Details
IBI-3002	IBI3002; IBI-3002	Phase 2 Clinical		Asthma; Dermatitis, Atopic	Details
MG-ZG122	MG-ZG122; MGZG122	Phase 2 Clinical	Shanghai Mabgeek Biotechnology Co Ltd	Asthma; Pulmonary Disease, Chronic Obstructive	Details
AZD-8630	AZD-8630; AMG-104	Phase 2 Clinical	Amgen Inc, Astrazeneca Plc	Asthma	Details
TAVO-101	TAVO-101; TAVO101	Phase 2 Clinical	Tavotek Biotherapeutics (Hong Kong) Ltd	Dermatitis, Atopic; Hypersensitivity	Details
PF-06342674	RN-168; PF-6342674; PF-06342674; ZB-168	Phase 1 Clinical	Pfizer Inc	Diabetes Mellitus, Type 1; Multiple Sclerosis	Details
APG273	APG273; APG-273	Phase 1 Clinical	Apogee Therapeutics Inc	Asthma; Pulmonary Disease, Chronic Obstructive	Details
HBM-7575	HBM-7575; SKB575; SKB-575; HBM7575	Phase 1 Clinical	Harbour Biomed	Dermatitis, Atopic; Inflammation	Details
WIN-027	QX027N; QX-027-N; WIN027; WIN-027	Phase 1 Clinical	Qyuns Therapeutics Co Ltd	Asthma; Dermatitis, Atopic	Details
HB-0056	HB-0056; HB0056	Phase 1 Clinical	Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd	Asthma; Dermatitis, Atopic; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive	Details
APG-333	APG333; APG-333; PR018; PR-018	Phase 1 Clinical	Apogee Therapeutics Inc	Asthma	Details
SAR-444765	SAR444765; SAR-444765	Phase 1 Clinical	Sanofi	Inflammation	Details
BSI-502	BSI-502; ATI-052	Phase 1 Clinical	Biosion Inc	Autoimmune Diseases of the Nervous System; Inflammation	Details
CDX-622	CDX-622	Phase 1 Clinical	Celldex Therapeutics Inc	Asthma; Fibrosis; Hypersensitivity; Inflammation	Details
STSA-1201	STSA-1201; STSA1201	Phase 1 Clinical	Staidson(Beijing) Biopharmaceuticals Co Ltd	Asthma	Details
LQ043H	LQ043H	Phase 1 Clinical	Shanghai Novamab Biopharmaceuticals Co Ltd	Asthma	Details
GR2002	GR2002	Phase 1 Clinical	Genrix (Shanghai) Biopharmaceutical Co Ltd	Asthma; Dermatitis, Atopic; Nasal Polyps; Sinusitis	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indication	Clinical Trial
Tezepelumab	MEDI-9929; AMG-157	Approved	Amgen Inc	Tezspire	United States	Asthma	Astrazeneca Ab	2021-12-17	Anaphylaxis; Asthma; Bronchial Diseases; Carcinoma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilic Esophagitis; Granulomatosis with Polyangiitis; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Lung Diseases; Lung Diseases, Obstructive; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Respiratory Tract Diseases; Sinusitis	Details

Customer Reviews

S***n2023-06-10
Mouse TSLP Protein, His Tag (MALS verified)
We got the TSLP recombinant protein from your company. The plan was to stimulate cell in vitro to see if it can induce a TH2 response. Your company offers the most cost effective option for the TSLP protein and with good customer service and express shipping. So far we do see some level of responses in the cells, we will perform more testing to validate the effects. The quality of the protein seems quite good and worth trying.

Trending Searches:

TSLP

TSLP

TSLP Overview

TSLP Product List

Can’t find what you need?

When should fluorescent DLL3 proteins or DLL3-coupled beads be used instead of unconjugated protein?

How can soluble DLL3 protein and a DLL3 stable cell line be combined to reduce false-positive binders?

How should I choose among full extracellular DLL3 and shorter DLL3 fragments for antibody discovery?

How should cross-species TL1A binding be assessed before selecting an in vivo model?

Which TL1A format is best for controlled immobilization in binding assays?

Clinical Drug Information

Marketed Drug Information